{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:45:47Z","timestamp":1782733547829,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"DOI":"10.7759\/cureus.111710","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:08:59Z","timestamp":1782731339000},"source":"Crossref","is-referenced-by-count":0,"title":["Success of Deuruxolitinib (Leqselvi\u2122) in Extensively Treatment-Resistant Alopecia Universalis: A Case Report"],"prefix":"10.7759","author":[{"given":"Simona","family":"Kogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises","family":"Lutwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lutwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Skopit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2020.101264","article-title":"Immunology of alopecia areata","volume":"45","author":"\u017beberkiewicz M","year":"2020","unstructured":"\u017beberkiewicz M, Rudnicka L, Malejczyk J. Immunology of alopecia areata. Cent Eur J Immunol. 2020, 45:325-333. 10.5114\/ceji.2020.101264","journal-title":"Cent Eur J Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing L","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et al.. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014, 20:1043-1049. 10.1038\/nm.3645","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5894","article-title":"Topographic phenotypes of alopecia areata and development of a prognostic prediction model and grading system: a cluster analysis","volume":"155","author":"Lee S","year":"2019","unstructured":"Lee S, Kim BJ, Lee CH, Lee WS. Topographic phenotypes of alopecia areata and development of a prognostic prediction model and grading system: a cluster analysis. JAMA Dermatol. 2019, 155:564-571. 10.1001\/jamadermatol.2018.5894","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94571","article-title":"Episodic neuropathic-like musculoskeletal pain associated with ritlecitinib therapy in alopecia universalis: a case report","volume":"17","author":"Bhardwaj S","year":"2025","unstructured":"Bhardwaj S, Aramandla S, Naveed A, Tu K, Mai TD. Episodic neuropathic-like musculoskeletal pain associated with ritlecitinib therapy in alopecia universalis: a case report. Cureus. 2025, 17:e94571. 10.7759\/cureus.94571","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1577115","article-title":"Janus kinase inhibitors for alopecia areata: a review of clinical data","volume":"16","author":"Sun Y","year":"2025","unstructured":"Sun Y, Li Q, Zhang Y, Liu Y. Janus kinase inhibitors for alopecia areata: a review of clinical data. Front Immunol. 2025, 16:1577115. 10.3389\/fimmu.2025.1577115","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01413.x","article-title":"Alopecia areata: clinical presentation, diagnosis, and unusual cases","volume":"24","author":"Finner AM","year":"2011","unstructured":"Finner AM. Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol Ther. 2011, 24:348-354. 10.1111\/j.1529-8019.2011.01413.x","journal-title":"Dermatol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S400247","article-title":"Perinevoid alopecia: report of two cases and literature review","volume":"16","author":"Zhang Y","year":"2023","unstructured":"Zhang Y, Zhang J, Zhou C. Perinevoid alopecia: report of two cases and literature review. Clin Cosmet Investig Dermatol. 2023, 16:1003-1008. 10.2147\/CCID.S400247","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7753.122959","article-title":"Canities subita: a reappraisal of evidence based on 196 case reports published in the medical literature","volume":"5","author":"Nahm M","year":"2013","unstructured":"Nahm M, Navarini AA, Kelly EW. Canities subita: a reappraisal of evidence based on 196 case reports published in the medical literature. Int J Trichology. 2013, 5:63-68. 10.4103\/0974-7753.122959","journal-title":"Int J Trichology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2020.06.001","article-title":"Brigham eyebrow tool for alopecia: a reliable assessment of eyebrow alopecia areata","volume":"20","author":"Tkachenko E","year":"2020","unstructured":"Tkachenko E, Huang KP, Ko JM, et al.. Brigham eyebrow tool for alopecia: a reliable assessment of eyebrow alopecia areata. J Investig Dermatol Symp Proc. 2020, 20:S41-S44. 10.1016\/j.jisp.2020.06.001","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King B","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, et al.. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024, 91:880-888. 10.1016\/j.jaad.2024.06.097","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1553904","article-title":"Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report","volume":"16","author":"He Y","year":"2025","unstructured":"He Y, Qi J, Wu Z, Zhang J, Zhang G. Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report. Front Immunol. 2025, 16:1553904. 10.3389\/fimmu.2025.1553904","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4090","article-title":"Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis","volume":"160","author":"Ingrassia JP","year":"2024","unstructured":"Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, Garshick MS. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024, 160:28-36. 10.1001\/jamadermatol.2023.4090","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70258","article-title":"Real-world safety of JAK inhibitors in skin immune-mediated inflammatory diseases: boxed warning outcomes from a multinational cohort study","volume":"119","author":"Lin TL","year":"2026","unstructured":"Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Real-world safety of JAK inhibitors in skin immune-mediated inflammatory diseases: boxed warning outcomes from a multinational cohort study. Clin Pharmacol Ther. 2026, 119:1628-1637. 10.1002\/cpt.70258","journal-title":"Clin Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.5509","article-title":"Short-term cardiovascular complications in dermatology patients receiving JAK-STAT inhibitors: a meta-analysis of randomized clinical trials","volume":"160","author":"Ireland PA","year":"2024","unstructured":"Ireland PA, Jansson N, Spencer SK, Braden J, Sebaratnam D. Short-term cardiovascular complications in dermatology patients receiving JAK-STAT inhibitors: a meta-analysis of randomized clinical trials. JAMA Dermatol. 2024, 160:281-289. 10.1001\/jamadermatol.2023.5509","journal-title":"JAMA Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2404","article-title":"Immune-mediated and psychiatric comorbidities among patients newly diagnosed with alopecia areata","volume":"160","author":"Mostaghimi A","year":"2024","unstructured":"Mostaghimi A, Soliman AM, Li C, Barqawi YK, Grada A. Immune-mediated and psychiatric comorbidities among patients newly diagnosed with alopecia areata. JAMA Dermatol. 2024, 160:945-952. 10.1001\/jamadermatol.2024.2404","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg SR","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al.. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022, 386:316-326. 10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/506855-success-of-deuruxolitinib-leqselvi-in-extensively-treatment-resistant-alopecia-universalis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:09:00Z","timestamp":1782731340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/506855-success-of-deuruxolitinib-leqselvi-in-extensively-treatment-resistant-alopecia-universalis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.111710","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}